Baseline Plasma Gas6 Protein Elevation Predicts Adverse Outcomes in Hospitalized COVID-19 Patients

Table 3

Comparison of plasma Gas6, sAxl, and sMerTK concentrations at different time points (t0, t7, and t14) between patients with a faster recovery (discharged from hospital and/or within 14 days) and all the other patients. Values are expressed as median (IQR). Bold text highlights the statistically significant results.

Laboratory findings (ng/ml)	Faster clinical recovery ()	All other patients ()		value
Gas6
t0	46.44 (38.8-58.0)	48.9 (36.8-67.6)	-1.116	0.264
t7	32.5 (26.9-47.0)	39.9 (33.7-45.9)	-1.201	0.230
t14	29.7 (23.6-41.1)	36.8 (32.9-51.2)	-1.683	0.092
sAxl
t0	16.9 (11.8-28.5)	15.9 (9.7-22.4)	0.992	0.321
t7	26.4 (15.9-45.0)	24.1 (10.7-35.2)	1.241	0.214
t14	23.3 (17.4-29.8)	20.3 (15.2-32.3)	0.066	0.947
sMerTK
t0	32.3 (25.5-37.0)	37.0 (25.3-41.4)	-2.135	0.033
t7	26.6 (20.1-31.7)	32.6 (22.1-38.3)	-2.015	0.044
t14	24.6 (20.6-32.5)	24.1 (21.2-28.1)	-0.022	0.982